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value associated with convenience in health care delivery, independ-
ent of health outcomes, and to try to estimate the likely magnitude of
any value found. Methods: A systematic search was conducted for
previously published studies that reported preferences for
convenience-related aspects of health care delivery in a manner that
was consistent with either cost-utility analysis or cost-beneﬁt analy-
sis. Data were analyzed in terms of the methodologies used, the
aspects of convenience considered, and the values reported. Results:
Literature searches generated 4715 records. Following a review of
abstracts or full-text articles, 27 were selected for inclusion. Twenty-
six studies reported some evidence of convenience-related process
utility, in the form of either a positive utility or a positive willingness
to pay. The aspects of convenience valued most often were mode of
administration (n ¼ 11) and location of treatment (n ¼ 6). The mostee front matter Copyright & 2014, International S
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ndence to: L. Longworth, Health Economics Researcommon valuation methodology was a discrete-choice experiment
containing a cost component (n ¼ 15). Conclusions: A preference for
convenience-related process utility exists, independent of health out-
comes. Given the diverse methodologies used to calculate it, and the
range of aspects being valued, however, it is difﬁcult to assess how large
such a preference might be, or how it may be effectively incorporated
into an economic evaluation. Increased consistency in reporting these
preferences is required to assess these issues more accurately.
Keywords: health care, preference elicitation, process utility,
systematic review.
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Quality-adjusted life-years (QALYs) reﬂect the health beneﬁts
gained from an intervention in terms of additional years of life
and health-related quality of life [1,2]. Recent years have seen an
increased level of interest in the deﬁnition and valuation of
health care outcomes beyond those traditionally encapsulated
by QALYs. The QALY framework, commonly used in the eco-
nomic evaluation of health interventions, including by the
National Institute for Health and Care Excellence (NICE) in the
United Kingdom, focuses on health beneﬁts gained from an
intervention and does not take account of other potential effects
of health care. Recently, NICE in the United Kingdom has
recognized the importance of other health care outcomes in its
updated version of the Guide to the Methods of Technology Appraisal.
Although NICE still focuses on health effects for its reference case
analysis, it now allows consideration of evidence on the “process
characteristics” of health care technologies that have a value to
people independently of any direct effect on health, such as
improving convenience in delivery and administration of care,
and the level of information provided to patients [3]. Others have
also recently proposed considering a broader range of deﬁnitionsof outcomes of health care, including the role of happiness in
health valuation [4] and measuring both health and nonhealth
beneﬁts when evaluating more complex health interventions [5].
The assumption that health gain is the only relevant outcome of
an interventionmay lead to a neglect of other factors that potentially
ought to be valued. This has been well articulated in the past by
Mooney [6], who points out that within the patient’s utility function,
other characteristics of “health care,” beyond the relatively narrow
deﬁnition of “health,” are unacknowledged. These other character-
istics are encompassed within the term “process utility,” an umbrella
term for the utility gained from the nonhealth aspects of health care
that patients experience, independent of the ultimate health-related
outcome. Not incorporating process utility into the overall valuation
of utility from health care could therefore potentially lead to a
suboptimal provision of health care [7] because health care allocation
will not have taken all relevant characteristics into account.
The importance of nonhealth outcomes of health care is
recognized in existing health policies, which may have wider
goals, beyond the sole objective of improving health outcomes. In
the United Kingdom, policies have been introduced that address
nonhealth outcomes such as the reduction in mixed-sex wards to
maintain the privacy and dignity of patients [8]. Other changes inociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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health care services, also have potential to have an impact on
process utility. A NICE-commissioned report into the value of
innovation and other beneﬁts in the United Kingdom [9], distinct
from improved health outcomes, suggested that beneﬁts that
could potentially make a “real difference” to patients are not all
being valued and that other aspects of care that matter to
patients are being overlooked.
Of course, the optimal resource allocation in any individual
health system depends on the objectives of that system. If the
objective is purely to maximize health, then it could be argued
that any value derived from a process is irrelevant. If, however,
the objective is to maximize well-being or to align resources to
the preferences of the population served by the system, then a
consideration of process-related outcomes is potentially impor-
tant because without this, the values assigned to health care
technologies could fail to reﬂect the true value of care to patients.
Aiming to measure process utility as part of a wider attempt to
maximize well-being is also in accordance with the deﬁnition of
health given by the World Health Organization, describing health
as a state of “complete physical, mental and social well-being,
and not merely the absence of disease or inﬁrmity” [10].
Process utility encapsulates values arising from a wide range
of health care characteristics, from the practical—such as the
frequency of administration of a given treatment—to the more
conceptual and abstract, for example, dignity. As with other
forms of utility, process utility reﬂects a continuum on which
the magnitude of values is likely to vary between aspects of
health care, the circumstances in which they are delivered, and
individuals’ preferences. One recent review [11] reported studies
looking at measurements of process utility in general. In compar-
ison, this review focuses speciﬁcally on process utility associated
solely with the convenience of health care provision. It also
reports preference measurements, such as willingness to pay
(WTP), which could be incorporated into cost analyses and
economic evaluations that fall outside the traditional QALY [11].
Preferences related to convenience are relevant to a range of
health interventions. For example, preferences toward waiting
time or distance from care will clearly be relevant to higher-level
decisions around the regionalization or centralization of health
services. Convenience-related process utility may also be an issue
in the assessment of pharmaceuticals and other health technol-
ogies. Increasingly, new developments in health care technologies
are not related solely to health gains but to developments relating
to the frequency or mode of administration. These innovations
may have value to patients beyond any effect on patient health (e.
g., an improvement in health outcomes deriving from improved
concordance with treatment regimens) if they make disease
management easier and more convenient. To date, little research
has been conducted around the magnitude of such effects. If the
worth of these process characteristics is shown to be of sufﬁcient
magnitude, their valuation relative to health effects would allow
their inclusion in health technology assessments (HTAs).
It was therefore timely and appropriate to examine the
evidence to date surrounding the existence of convenience-
related process utility and to establish whether patients care
only about the health beneﬁts they receive or whether they also
care about the manner in which these beneﬁts are delivered. The
aim of this study was to establish whether people value conven-
ience in health care and estimate the likely magnitude of those
values by systematically reviewing the published evidence.Methods
Literature searches were performed in two databases—Ovid MED-
LINE and Scopus—in June 2013. Search strategies are outlined inAppendix A in Supplemental Materials found at http://dx.doi.org/%
2010.1016/j.jval.2014.08.2670. No date or language limitations were
applied. Only full articles were included for consideration; confer-
ence materials and abstracts were excluded because these were not
expected to provide details of methods and results in sufﬁcient
detail. To be considered for inclusion, articles needed to assess
preferences for a convenience-related aspect of a treatment or
intervention, including (but not restricted to) the following: distance
to travel, duration of intervention, frequency of intervention,
location/setting, mode of administration, or waiting time. Articles
were restricted to those reporting preferences on a scale compatible
with inclusion in the cost-utility analysis framework (standard
gamble [SG] or time trade-off [TTO]) or cost-beneﬁt analysis (con-
tingent valuation including WTP). Data from discrete-choice experi-
ments (DCEs) were included if the experiment contained a cost
attribute (e.g., cost per month) from which a WTP estimate could be
derived. DCEs without a ﬁnancial attribute were not included.
Two researchers (A.H. and J.S.) screened all titles and abstracts
for eligibility. Discrepancies were resolved via consultation with a
third researcher (L.L.), who made the ﬁnal decision when con-
sensus could not be reached. Full-text versions of all potentially
relevant articles were obtained, and reviewed by A.H. using the
same inclusion criteria. Articles that met preset inclusion criteria
were included in the review.
A data extraction template was developed and implemented as
a Microsoft Excel workbook and used to extract relevant data from
the included articles. A range of data was extracted. Points of key
interest included aspect of convenience valued, valuation method-
ology used, value of the utility, and any overall conclusions that
could be drawn from the article with respect to process utility.
The data identiﬁcation process is represented graphically
using a Preferred Reporting Items for Systematic Reviews and
Meta-Analyses ﬂow chart in Figure 1 [12].
All ﬁnancial values were converted to Great Britain pounds
using a currency conversion Web site (www.xe.com) and updated
to 2012 values (the most recent available) to allow for ease of
comparison.Results
Search Results
Initial searches identiﬁed 4355 results in MEDLINE and 360 in
Scopus. Following the screening of unsuitable titles and abstracts
and removal of duplicates, 39 abstracts were determined to meet
the speciﬁed inclusion criteria (30 from MEDLINE and 9 from
Scopus). These articles were obtained and reviewed in full
according to the original inclusion criteria. Twenty-seven articles
were identiﬁed as meeting the inclusion criteria and were
brought forward for data extraction.
Key Characteristics of Studies
Studies identiﬁed and reviewed were published between 1996 and
2013, and came from Canada (n ¼ 7) [13–19], the United States (n ¼
3) [20–22], the United Kingdom (n ¼ 3) [23–25], Scotland (n ¼ 3) [26–
28], Australia (n ¼ 3) [29–31], Sweden (n ¼ 2) [32,33], Denmark (n ¼
1) [34], Germany (n ¼ 1) [35], Italy (n ¼ 1) [36], and Spain (n ¼ 1)
[37]. Two studies had multinational perspectives [38,39]. Study
characteristics are expanded upon in Table 1.
Aspects of convenience valued can be classiﬁed broadly into two
categories: Those relating to the administration of an intervention,
for example, dosing frequency or mode of administration
[13,15,18,19,21,23,24,26,30–34,36–39], and those looking at ease of
access to an intervention, for example, distance to travel [14,16,
17,20,25,28,29,35]. Two studies spanned both categories [22,27].
Records identified through database searching
(n = 4715)
Records excluded and 
duplicates removed
(n = 4676)
Full-text articles assessed for eligibility
(n = 39)
Full-text articles excluded
(n = 12)
Primary reasons for 
exclusion:
Not pertaining to 
terms specified by 
the authors (n=8)
No clear WTP or 
utility component
(n=4)Studies included in 
synthesis 
(n = 27)
Fig. 1 – Flow diagram of systematic review to identify included studies.
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from study to study, even when the concepts being described
were fundamentally the same. For example, three studies
[14,20,29] assessed preferences for home treatment versus treat-
ment in a clinical setting. In these studies, the descriptions of the
attribute being valued (home treatment) were quite uniform, and
assumed identical levels of safety and efﬁcacy in all treatment
settings, thus assessing solely the convenience of receiving care
in the home environment. (This was modiﬁed slightly in Coley
et al. [20], in which the pragmatic assumption was made that
increasing levels of disease severity would automatically require
higher levels of hospital care.)
Preference-elicitation methods included SG (n ¼ 2) [20,26], WTP
(n ¼ 8) [14,18–21,29,33,35], and TTO (n ¼ 3) [23,30,31] (Table 2). A
substantial proportion of the studies (56%) took the form of a DCE,
using a ﬁnancial or cost-related attribute to derive a WTP valu-
ation for convenience [13,15–17,22,24,25,27,28,32,34,36–39].
Considering ﬁrst the studies using the SG approach, Boye et al.
[26] used traditional upper anchors of “perfect health,” assigned a
utility value of 1, and “worst health state,” assigned a value of 0,
subsequently adjusted so that the lower anchor, with a value of 0,
was representative of death. This was done using the chained
method developed by Torrance. Chaining is used when the
disability health states to be measured are mild, making it appear
unrealistic to compare them directly with death. Instead, states
are measured relative to an anchor state worse than the state of
interest. A second measurement then measures this state rela-
tive to death. The situation arises most often with the SG but can
also apply to the TTO [40,41]. The SG component of Coley et al.’s
methodology was similar, using upper and lower anchors of
“usual health” and “death,” respectively [20].
Three studies used TTO techniques to elicit preferences
[23,30,31]. TTO techniques value health states by quantifying
how much, if any, life expectancy people are willing to forego (or
“trade off”) to avoid that state [42]. One study [23] obtained utility
values from patients for hypothetical treatment scenarios usingtwo methods: a chained TTO design and by reporting expected
responses to the EQ-5D questionnaire. For all scenarios, respond-
ents attached higher utilities to the more “convenient” interven-
tion—in this case, inhaled versus injected insulin—when the TTO
design was used. Marginal utility ranged from 0.1 to 0.14 using
TTO methodologies and from 0.03 to 0.06 using EQ-5D question-
naire data [23]. These differing values for identical clinical
scenarios are suggestive of a greater sensitivity in TTO method-
ologies for process-related factors, indicating that they may be an
appropriate design for future preference elicitation studies. The
other two TTO studies [30,31] examined the utility associated
with the mode and duration of administration. Both reported a
mean marginal increase in utilities associated with the more
convenient intervention (Table 2)—Johnson et al. [30] reported an
increase from 0.475 to 0.837. Patients were not asked to explain
their preferences in the study, and it is therefore not possible to
establish the reasons behind this substantial increase; however,
it is possible that some respondents considered potential health
impacts, in addition to convenience, resulting from intravenous
administration (e.g., risk of infection). Nevertheless, together
these estimates suggest that not accounting for process utility
may have an impact on accurate assessment of patient
preferences.
Substantial variation was observed between studies in the use
of different WTP methodologies. The WTP component of Coley
et al.’s [20] study used a standard bidding approach to ascertain
respondents’ WTP to remain in usual health, and to avoid more
severe health states. Marra et al. [14] used open-ended WTP,
while the DCE studies required respondents to select a value from
a set of prespeciﬁed levels [13,15,17,28,29,33–36,38]. Both these
designs have the potential to lead to bias.
Looking at evidence of preferences, of the 27 studies reviewed,
all but one found evidence of preferences for convenience-related
utility (Table 3). Although preference values varied substantially
between studies—and within studies, in the case of multinational
studies—the existence of the preference itself seemed clear. The
Table 1 – Study characteristics.
S. no. Study Year Country Intervention Patient description Age
(mean)
(y)
Sex
(%
male)
1 Aristides
et al. [38]
2004 France, Germany,
Spain, Italy, United
Kingdom
Insulin treatment for type 2
diabetes
European diabetic patients aged 18–70 y receiving regular
insulin mix injections
51 46
2 Aust et al.
[35]
2011 Germany Preferences for anesthetic
treatment
Patients aged 14–86 y undergoing anesthetic treatment NR* NR
3 Bogelund
et al. [34]
2011 Denmark Insulin treatment for type 2
diabetes
Danish diabetic patients NR 66
4 Boye et al.
[26]
2011 Scotland Injectable insulin treatment for
type 2 diabetes
Patients with type 2 diabetes, age 30–75 y 59 66
5 Chancellor
et al. [23]
2008 United Kingdom Inhaled/injectable insulin treatment
for type 1/type 2 diabetes
UK diabetic adults 18 y or older 58 66
6 Coley et al.
[20]
1996 United States Low-risk community-acquired
pneumonia (CAP)
Patients older than 18 y enrolled in treatment for CAP
(hospitalized or outpatient)
44 37
7 Darba et al.
[37]
2011 Spain Prevention of osteoporosis
fractures
Patients with osteoporosis 69 5
8 Guimaraes
et al. [13]
2009 Canada Inhaled/injectable insulin treatment
for type 1/type 2 diabetes
Diabetic patients 19 y or older using oral antihypoglycemic
agents or insulin
57 52
9 Hodgkins
et al. [39]
2012 United States, United
Kingdom, Germany,
Canada
5-Aminosalicylic acid for ulcerative
colitis (UC)
Patients 18 y or older diagnosed with mild to moderate UC
(self-reported)
NR NR
10 Jampel et al.
[21]
2005 United States Eyedrops for glaucoma Adult patients receiving follow-up for glaucoma or
suspicion of glaucoma
66 46
11 Jendle et al.
[32]
2012 Sweden Liraglutide for type 2 diabetes Swedish patients with type 2 diabetes NR NR
12 Johnson
et al. [30]
1996 Australia Maintenance antiviral treatment
for cytomegalovirus (CMV)
retinitis infection
Patients with conﬁrmed HIV infection but without CMV
retinitis
NR 499
13 Landfeldt
et al. [33]
2012 Sweden Ovarian stimulation treatments Women undergoing IVF treatment 35 0
14 Marra et al.
[14]
2005 Canada Outpatient parenteral antibiotic
therapy (OPAT)
Adult patients eligible for OPAT requiring antibiotics for
expected minimum of 5 d and living in suitable home
environment
56 69
15 McTaggart-
Cowan
et al. [15]
2008 Canada Asthma therapy Patients aged 19–49 y with physician-diagnosed asthma
and no concurrent respiratory conditions
35 30
16 Moia et al.
[36]
2013 Italy Anticoagulant therapy Patients on stable vitamin K anticoagulants for 46 mo or
about to start a therapy course
64 55
17 Osborne
et al. [31]
2007 Australia Deferoxamine treatment for
chronic iron overload
Convenience sample of the general public NR 50
18 Ossa et al.
[24]
2007 United Kingdom Erythropoietin treatment in
chemotherapy-related anemia
Convenience sample of the general public aged 418 y 45 42
19 Oteng et al.
[16]
2011 Canada HPV and cervical cancer screening Representative sample of Canadians aged 419 y 44 51
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V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 8 7 7 – 8 8 7 881highest valuation assigned by a WTP study was a one-off pay-
ment of £239.25 (95% conﬁdence interval £223.30–255.20) for the
use of a preﬁlled pen versus a conventional syringe in the
administration of insulin for diabetes treatment [33].
The study that found a disutility associated with convenience-
related attributes [28] examined preferences surrounding the
frequency of cervical cancer screening. Respondents expressed
a WTP for more frequent screening (a marginal WTP of £16.54 per
1-year decrease in screening intervals). It is likely that this is due
to the preventive nature of the intervention in question—that the
perceived future avoidance of health problems (and associated
inconveniences) would outweigh any inconvenience incurred by
the preventive screening itself. Oteng et al. [16], however, also
examined preferences surrounding human papillomavirus and
cervical cancer screening: Their results, in contrast to those of
Wordsworth et al. [28], found evidence of preferences for reduced
frequency of screening (a negative WTP of £4.54 for an annual
smear test compared with a positive valuation of £17.52 for a
reduction in frequency to once every 3 years). Neither study held
health constant, that is, explicitly stated that changes in other
attributes would not have an impact on health outcomes. This
means that there may be other, unobservable interactions hap-
pening between health states and other attributes within either
or both the studies that have not been identiﬁed or accounted for
in the results. The contradiction between the two studies is
indicative of some of the complexities surrounding the issue of
process utility, and the challenges involved in untangling
preferences.Discussion
This review has identiﬁed studies reporting utility and monetary
estimates for convenience-related utility. The results point to a
modest, but positive, value placed by patients and the public on
convenience-related aspects of health care. The values provided
in the studies were varied and reﬂect the large degree of
methodological variability exhibited in the studies, as well as
the range of different aspects of convenience considered.
The implications of failing to take account of process utility
are manifold. If process utility is not appropriately incorporated
into economic evaluations, there is a risk of suboptimal
resource allocation. Factors such as social value judgments
merit consideration, and perspectives may need to be adjusted
to reﬂect the true utility of an intervention, particularly when
the external, process-related beneﬁts are likely to be substan-
tially greater than any displaced health-related ones [43]. If
process factors are not taken into consideration when health
care resources are being allocated, there will be a misalignment
between the stated aims of health care policy and the realities
of resource use.
Whether this is actually the case, and to what extent, depends
on the magnitude of the utility derived from not only the process
but also health gain and the cost of the intervention. The focus
should not be on promoting process utility above all other
decision-making factors but on developing a balanced view of
the overall costs and utilities associated with an intervention.
The valuation of process outcomes relative to health gain can
provide useful information to health care decision makers.
Valuation in this way is arguably more consistent with HTA
frameworks that focus on incremental cost-per-QALY or life-year
analyses. It also explicitly reﬂects the potential trade-off in the
decision problem faced by health care providers: When faced
with a resource constraint, is the opportunity cost (in terms of
health lost) worth the gain derived from improvements in
process of care [3]? Finally, valuing process relative to health
gain may facilitate comparison with existing explicit and implicit
Table 2 – Methods of elicitation.
S. no. Author n Convenience-related attribute(s) Method of elicitation
1 Aristides et al. [38] 235 Timing of injection relative to meals WTP values obtained via questionnaire. Values derived
using preferences for two other attributes relative to
cost within DCE.
2 Aust et al. [35] 1014 Location of visit WTP values obtained via questionnaire. Values derived
using the proportions of a ﬁxed sum of money
respondents were willing to allocate to a particular
attribute.
3 Bogelund et al. [34] 270 1) Mode of administration
2) Method of blood glucose monitoring
WTP values obtained via questionnaire. Values derived
using preferences for four other attributes relative to
additional payments within DCE.
4 Boye et al. [26] 151 1) Dose frequency
2) Dose ﬂexibility
SG values obtained in interviews. Health states
described in terms of injection site reaction,
frequency, and ﬁxed/ﬂexible dose, and valued on a
scale of worst health to perfect health (1), then
rescaled by valuing worst health state relative to
death (0).
5 Chancellor et al.
[23]
344 Mode of administration Chained TTO values obtained in interviews. First trade-
off between treatment components of a scenario pair
(e.g., inhaled or injectable insulin), then second
trade-off between less preferred scenario and full
health.
6 Coley et al. [20] 159 Treatment location—home or
hospital setting
1) SG values obtained in interviews. Values anchored as
usual health (1) and death (0).
2) WTP values obtained for preferred location/scenario,
presented as maximum proportion of monthly income
using a bidding approach.
7 Darba et al. [37] 166 1) Levels of administration
2) Place of administration
WTP values obtained via questionnaire. Values derived
using preferences for two other attributes relative to
cost within DCE.
8 Guimaraes et al.
[13]
274 Mode of administration WTP values obtained via questionnaire. Values derived
using preferences for ﬁve other attributes relative to
monthly out-of-pocket payment with DCE.
9 Hodgkins et al. [39] 400 1) Ease of swallowing
2) Time of day
3) Quantity
WTP values obtained via questionnaire. Values derived
using preferences for ﬁve other attributes relative to
monthly cost within DCE.
10 Jampel et al. [21] 230 Characteristics of eyedrops: Dosing
frequency and number of bottles
WTP values obtained in interviews. Framed as out-of-
pocket expense with/without co-payment.
11 Jendle et al. [32] 461 Mode of administration WTP values obtained via questionnaire. Values derived
using preferences for other attributes relative to out-
of-pocket payment within DCE.
12 Johnson et al. [30] 80 1) Duration of treatment
2) Mode of administration
TTO values obtained via interview.
13 Landfeldt et al. [33] 294 1) Mode of administration
2) Frequency of administration
3) Dose variability
WTP values obtained via questionnaire. Contingent
valuation question asked participants whether they
would make an out-of-pocket payment of x to
receive one set of treatment attributes instead of
another.
14 Marra et al. [14] 91 Treatment location—home or
hospital setting
WTP values obtained via questionnaire using an open-
ended WTP approach.
15 McTaggart-Cowan
et al. [15]
157 1) Dose per day
2) Number of inhalers
WTP values obtained via questionnaire. Values derived
using preferences for six other attributes relative to
cost per month within DCE.
16 Moia et al. [36] 255 1) Mode and frequency of
administration
2) Monitoring frequency
3) Interactions with drugs or food
4) Need of dose adjustment
5) Risk of minor symptoms
WTP values obtained via questionnaire. Values derived
using preferences for ﬁve other attributes relative to
cost per month within DCE.
17 Osborne et al. [31] 110 Mode of administration TTO values obtained via interview.
18 Ossa et al. [24] 110 Duration, mode, and location of
administration
WTP values obtained via interview. Values derived
using preferences for ﬁve other attributes relative to
cost within DCE.
continued on next page
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Table 2 – continued
S. no. Author n Convenience-related attribute(s) Method of elicitation
19 Oteng et al. [16] 1157 Frequency of screening WTP values obtained via questionnaire. Values derived
using preferences for six other attributes relative to
cost within DCE.
20 Phillips et al. [22] 354 1) Location
2) Ease of results collection
WTP values obtained via questionnaire. Values derived
using preferences for other attributes relative to out-
of-pocket payment within DCE.
21 Porteous et al. [25] 326 “Availability”—waiting time, travel
time, and duration of treatment
WTP values obtained via questionnaire. Values derived
using preferences for two other attributes relative to
cost within DCE.
22 Roux et al. [17] 165 Travel time WTP values obtained via questionnaire. Values derived
using preferences for four other attributes relative to
cost within DCE.
23 Wordsworth et al.
[28]
577 Frequency of screening WTP values obtained via questionnaire. Values derived
using preferences for four other attributes relative to
cost within DCE.
24 Watson et al. [27] 149 1) Location
2) Mode of screening
WTP values obtained from interviews. Values derived
from preferences for four other attributes relative to
one-off cost within DCE.
25 Sadri [18] 120 Mode of administration WTP values obtained via interview using a close-ended
WTP approach.
26 Sadri et al. [19] 96 Mode of administration WTP values obtained via interview using a close-ended
WTP approach.
27 Whitty et al. [29] 91 Treatment location—home or
hospital setting
DCE values for clinic-based vs. home-based programs
obtained via interview. WTP values for preferred
program and estimated travel costs also obtained via
interview using dichotomous bidding approach.
DCE, discrete-choice experiment; SG, standard gamble; TTO, time trade-off; WTP, willingness to pay.
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of QALYs (or life-years gained) [44].
This recognition of the importance of value not directly related to
health has recently been incorporated into NICE guidelines [3].
Although the guidelines do not currently recommend inclusion of
process utility values into reference-case analyses—possibly due to
differences in standard methodologies for eliciting preferences
toward health and process outcomes, among other reasons—con-
sideration of supporting evidence on these process characteristics is
encouraged. NICE guidelines are an important indicator of the
increasing relevance process utility has for decision makers, as well
as the increasing urgency to develop appropriate quantitative meth-
ods to address it. The evidence reviewed here shows that preferences
for convenience-related process utility are shown to exist across a
wide spread of disease areas, and for various different aspects of
health care, provided that elicitation methods give respondents the
opportunity to express these preferences. Perhaps the challenge is to
focus on the incorporation of these methodologies alongside typical
health outcome metrics currently in use. This would help to add to
the relatively small body of evidence currently in existence. Impor-
tantly, it may also lead to a shift in the way people think about
nonhealth outcomes, by normalizing their valuation; they may in
time come to be seen as an integral aspect of economic evaluation.
Sometimes, there will inevitably be an overlap between con-
venience and health outcomes. The best example of this is the
relationship between administration and adherence. Making a
treatment easier to administer or reducing the frequency of
administration is likely to have a positive impact on adherence
and concordance rates across a range of disease areas [45–47].
Improved adherence will result in improved health outcomes,
which will be accounted for within the traditional QALY calcu-
lation. The evidence found in this review, however, suggest that
process utility is valued, to some extent, for itself and not just forany indirect health gains that it may bring about. The challenge lies
in identifying the point at which process and health gain utility no
longer overlap, and quantifying the “pure” process utility.
This reviewwas not without limitations. The search strategy was
restricted to articles published in peer-reviewed journals, meaning
that informally published or less accessible “gray” literature of
potential relevance may have been overlooked. It is possible that
some other useful indications of preferences for process utility may
not have been incorporated, particularly from more qualitative
studies. Although these sources may have indicated whether the
process of care is of importance to people, the aim of the review was
to identify measures that could be incorporated into an economic
evaluation, and therefore the focus was on compatible quantitative
analyses. The ambiguity surrounding concepts of process utility
may also have led to useful literature not being identiﬁed, speciﬁ-
cally the lack of standardized terminology describing process utility
and the broad range of health care characteristics that may affect it.
Furthermore, as for many reviews of this type, we cannot rule out
the possibility of publication bias whereby studies ﬁnding “negative”
or “null” results may not have been published.
In addition, the studies included in the review are themselves
subject to individual limitations. Some studies included in the review
had relatively small sample sizes: 10 of the 27 studies reported a
sample size of fewer than 200 [15,17–19,21,24,27,29–31], with 1 study
[30] having just 80 respondents. This has clear implications in terms
of the generalizability of the results. The generalizability of the
studies to other settings is also likely to be limited. For example,
some studies identiﬁed are from jurisdictions with national health
services funded by central taxation, whereas others are from
insurance or co-payment systems, which could affect the results
obtained. Aristides et al. [38] looked at WTP for attributes of insulin
treatment in ﬁve European countries, all with some type of national
health care system. WTP valuations not only varied very
Table 3 – Evidence of convenience-related process utility.
S. no. Author Evidence Form of evidence
£ Utility values
1 Aristides et al. [38] Yes Mean WTP per month: £36.17 for an
increase in dose frequency; £47.68 for a
decrease in frequency of nocturnal
hypoglycemic episodes
2 Aust et al. [35] Yes WTP: £14.41 for home setting instead of
clinical one
3 Bogelund et al. [34] Yes Monthly WTP: One fewer injection per day
(£34.23); able to inject irrespective of
mealtimes (£26.13); oral administration
instead of injection (with respect to
meals) (£46.85); oral administration
instead of injection irrespective of
mealtimes (£20.72)
4 Boye et al. [26] Yes Marginal increase in utilities: 0.023 for
weekly instead of daily injection; 0.006
for increased dosing ﬂexibility around
mealtimes
5 Chancellor et al.
[23]
Yes Marginal increase in utilities for inhaled vs.
injected insulin across a range of
scenarios: 0.08, 0.04, 0.04, 0.02, 0.01
6 Coley et al. [20] Yes Monthly median (interquartile range) WTP
(% of household income): For
uncomplicated health states, WTP for
home care is 5% (1%–20%) and hospital
care is 10% (2%–25%). For serious health
states, WTP for both hospital and home-
hospital is 30%, with respective ranges of
1%–80% and 10%–75%.
Marginal increase in utilities: For
uncomplicated and delayed health
states, home treatment preferred to
hospital by 0.001 (0.994–0.993). For
serious health states, a combination of
home-hospital treatment preferred to
hospital alone by 0.003 (0.98–0.995)
7 Darba et al. [37] Yes Marginal WTP: Daily oral administration
relative to daily subcutaneous injection
(£127.07) or annual intravenous injection
relative to daily subcutaneous injection
(£163.76), and self-administration
relative to administration at home with
support (£52.79)
8 Guimaraes et al.
[13]
Yes Mean WTP: £8.05 for oral administration
vs. subcutaneous injection (long acting);
£23.29 for inhaled administration and
£2.21 for subcutaneous injection vs. oral
administration (short acting)
9 Hodgkins et al. [39] Yes Marginal WTP: Reduction in frequency of
dosage from twice to once daily (£18.40
[Canada], £5.16 [Italy], £6.29 [United
Kingdom], £0.85 [United States]), and
reduction in quantity of tablets from two
to one (£2.80 [Canada], £2.60 [Italy], £4.24
[United Kingdom], £4.52 [United States])
10 Jampel et al. [21] Yes Mean WTP: Reduction in dosing frequency
from thrice to twice a day (£45.46), or
thrice to once a day (£51.02), or one
bottle of medicine instead of two (£46.58)
11 Jendle et al. [32] Yes WTP (£/d) for subcutaneous injection relative
to once daily oral administration of ros-
iglitazone (£1.04) or glimepiride (£0.65)
12 Johnson et al. [30] Yes Mean marginal increase in utilities
associated with oral relative to
intravenous therapy: 0.362 (0.837–0.475)
13 Landfeldt et al.
[33]
Yes WTP: Preﬁlled pen vs. conventional syringe
(£239.25), nonﬁlled pen vs. syringe
(£183.43), preﬁlled pen vs. nonﬁlled pen
(£55.83), and time for administration
(£23.93 per saved minute)
continued on next page
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Table 3 – continued
S. no. Author Evidence Form of evidence
£ Utility values
14 Marra et al. [14] Yes Mean WTP: Patients preferring home
setting (89%) £577.20, patients preferring
hospital setting (11%) £683.03
15 McTaggart-Cowan
et al. [15]
Yes Monthly WTP: Frequency of administration
—“as needed” preferred to once (£7.79),
twice (£31.79), or thrice (£60.93) daily;
number of inhalers—one preferred to
two (£20.51) or three (£18.88)
16 Moia et al. [36] Yes Marginal monthly WTP: £34.56 for
reduction in administration from twice
to once daily; £66.60 for oral daily
administration instead of weekly
subcutaneous injection
17 Osborne et al. [31] Yes Mean marginal increase in utilities: Oral
therapy relative to 1) anchor state (0.10)
[0.85–0.75] and 2) subcutaneous therapy
(0.24) [0.85–0.61]
18 Ossa et al. [24] Yes Monthly WTP: Reduction in duration of
administration (£0.15/min); method of
administration—cannula instead of sub-
cutaneous (£45.07) or intravenous (£8.41)
19 Oteng et al. [16] Yes Mean WTP £: Smear test frequency every
year (£4.67) or every 3 y (£18.03);
needing a HPV vaccine every 5 y
(£19.36) or never needing a booster
(£18.03)
20 Phillips et al. [22] Yes Marginal WTP: Ease of collection relative to
drawing blood—oral swab (£24.68), urine
sample (£22.04), or blood prick (£7.05).
Testing location relative to a public
health clinic—doctor’s ofﬁce (£18.51) or
at home (£13.22)
21 Porteous et al. [25] Yes WTP: £3.04 per 1-d increase in accessibility
of services
22 Roux et al. [17] Yes Marginal WTP: £4.77 per additional
15- min travel time
23 Wordsworth et al.
[28]
No Marginal WTP: £11.13 to increase screening
frequency by 1 y
24 Watson et al. [27] Yes Mean WTP: Method of screening—urine
test (£7.36) preferred to perineal swab
(£3.64) or full pelvic examination
(£3.72)
25 Sadri [18] Yes Monthly WTP: Inhaled vs. injectable
insulin: £39.81  £25.91
26 Sadri et al. [19] Yes Monthly WTP: Inhaled vs. injectable
insulin: £93.48  £60.76
27 Whitty et al. [29] Yes WTP: “Welfare gain” of £5.67 associated
with clinical care and £65.88 associated
with home care
HPF, human papillomavirus; WTP, willingness to pay.
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in the United Kingdom—but were also higher than initially hypothe-
sized. It is possible that respondents who are not used to paying for
treatment at the point of care will overstate values and the stated
preferences may not be an accurate representation of WTP values.
Other differences in the provision of health care between countries
could also limit the generalizability of results.
A high proportion of studies identiﬁed (81.4%) reported patient
preferences. Only 5 of the 27 studies reviewed reported preferences
of the general population. This may have led to some level of biasbecause patients are more likely to overstate values for therapies
that beneﬁt them personally. Two studies by Sadri [18] and Sadri
et al. [19] exemplify this: One [19] assessed diabetic patients’
valuations of inhaled insulin, resulting in a mean WTP of £93.48 
£60.76 (including the negative WTP values for patients who pre-
ferred injectable insulin). A subsequent study, 2 years later, of the
general public, found a comparable estimate of £39.81  £25.91 for
the same intervention [18]. Although results still express a prefer-
ence for convenience, valuations by members of the public are less
than half (44%) of what patients state they are willing to pay.
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elicitation were evident in several studies. For example, studies
using multiple preference elicitation methods found different
results for each method. In Coley et al. [20], the SG component
of the questionnaire generated much lower willingness to gamble
than did the corresponding WTP question. This is a manifestation
of an issue that has previously been associated with the SG
technique, namely, that many people may not be willing to accept
any possibility whatsoever of treatment failure when minor or
temporary states of poor health are being valued [48]. An addi-
tional confounding factor was the presence of some possible
framing issues surrounding the partially randomized ordering of
the questionnaires: it is unclear from the study, for example, why
the ordering of the category scaling and SG questions was
randomized, yet the WTP component always came third.
Some limitations previously reported for WTP studies of
health outcomes were also reported for these valuations of
process, for example, results spanning a huge range of values
for open-ended WTP questions [14], which can make it difﬁcult to
contextualize the value of the estimates obtained.
Limitations within some studies can be attributed to their
publication date. The oldest study in this review is by Johnson
et al. [30], predating the development of some of the instrumental
sensitivity with respect to process attributes that is evident in
more recent studies. This is acknowledged in other articles from
the period, such as Ryan et al. [49], who refer to “the insensitivity
of the WTP instrument to pick up the importance of particular
process attributes.” Similarly, Donaldson and Shackley [7] were
unable to establish the existence of process utility despite
respondents claiming that “process” factors were important to
them. They suggest that this may be because process utility
exists in a form that was not compatible with their chosen study
design [7]. More recent studies show much stronger evidence in
favor of the existence of process utility, which can reasonably be
attributed to advancements in study design.
A recent study looking at the incorporation of process utility in
general into a QALY framework found results very similar to those
reported here: all 15 studies reviewed showed evidence of utility-
based process utility [11]. The review was restricted to articles
showing empirical measures of process utility, that is, those
anchored on a scale of 0 representing death and 1 representing
full health. This search strategy would not pick up those DCE
articles involving a cost component, which comprise the majority
of this review’s ﬁndings. The authors acknowledge the potential
limitations of their study, some of which are shared by this
review, largely due to the lack of consistent terminology and
reporting of process-utility–related work. They conclude that
there is currently no sound methodological framework for the
incorporation of “process” into QALY frameworks and suggest the
exploration of alternative methodologies that may be appropriate
for the valuation of nonhealth outcomes, perhaps used in combi-
nation with more traditional approaches [11]. There is a growing
recognition that DCEs, for example, could potentially contribute to
outcome measurement [50]. Brennan and Dixon [11] also identify
alternative methods that may warrant further research, for
example, the use of psychometric approaches, comparative stud-
ies with other patient-reported measures, or the use of a process-
related “bolt-on” to an existing preference-based measure. Our
ﬁndings support the need for alternative methodologies to be
developed, which may include DCE, and the need for a more
consistent approach to the valuation of process utility.Conclusions
The conclusion to be drawn from the studies reviewed is that
convenience-related process utility does exist, although thispreference may be small in some cases. The studies reviewed
encompass a wide range of countries, methodologies, disease
areas, and attributes encompassed in the study. The fact that
such a large majority of studies (all but one) show the existence
of some level of preference for convenience despite substantial
changes in key factors such as study design and attribute
description is a promising indication of the robustness of such
a preference. The evidence from this review suggests that process
utility derived from improvements in convenience-related
aspects of health care may be small in magnitude; however, the
estimates provided in the studies are likely to be hampered by
difﬁculties in applying standard methods of health valuation to
value process characteristics.
One of the most striking factors of this review is the high
proportion of studies that use a DCE methodology, using some
kind of ﬁnancial attribute to derive a WTP estimation. The
relatively small proportion of studies using traditional forms of
utility assessment is to be expected, given their inherently
longer-term scope: attempting to value convenience in the con-
text of potential instantaneous death (as per the SG) is very likely
to induce ceiling effects, given the difference in magnitude
between the seriousness of the two concepts. The wide range
of methodologies reported makes it difﬁcult to meaningfully
compare estimates from the different sources. In addition, most
studies used a variant of WTP methods or a cost attribute in a
DCE to obtain monetary estimates of value. Although these
results can legitimately be used in a cost-beneﬁt analysis, they
cannot currently be incorporated into a QALY-based cost-effec-
tiveness framework. This leads to the issue of how these data can
be appropriately used in terms of their potential effect on health
care policy. Given the wide range of methodologies reported in
this review, each associated with its own potential for bias and
subjectivity, there seems to be a strong case to be made for
having a single recommended method of valuation with which to
examine the issue.
If process utility is to be incorporated routinely into HTA and
used to inform decision making, improved and consistent meth-
odologies are required. Growing interest in nonhealth outcomes
from HTA agencies and researchers, as evidenced by the reference
to process utility in NICE guidelines [3], makes reﬁnement of
existing methodologies or the development of new methodologies
increasingly urgent. Based on the results of this review, there is a
need for a more in-depth consideration of the most appropriate
methodologies to be used to ensure optimal resource allocation.
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